^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Eye Cancer

Related cancers:
1d
PLEK2: a potential biomarker for metastasis and prognostic evaluation in uveal melanoma. (PubMed, Front Med (Lausanne))
PLEK2 is upregulated in UVM and correlates with poor patient prognosis, likely influencing the calcium signaling pathway. PLEK2 represents a promising prognostic biomarker and therapeutic target for UVM.
Journal
|
PLEK2 (Pleckstrin 2)
2d
MMP9 in pan-cancer and computational study to screen for MMP9 inhibitors. (PubMed, Am J Transl Res)
CHEMBL82047 and CHEMBL381163 are ideal compounds for inhibiting MMP9. The findings of this study will contribute to the design and improvement of MMP9-targeting drugs.
Journal • Tumor mutational burden • Pan tumor
|
TMB (Tumor Mutational Burden) • MMP9 (Matrix metallopeptidase 9)
|
MMP9 overexpression
3d
RB functions as a key regulator of senescence and tumor suppression. (PubMed, Semin Cancer Biol)
Leveraging RB-mediated senescence presents promising opportunities for cancer therapy, including novel approaches in tumor immunotherapy designed to enhance treatment efficacy. This review highlights recent advancements in the RB signaling pathway, focusing on its roles in cellular senescence and tumor suppression, and discusses its potential to improve tumor management and clinical outcomes.
Review • Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
5d
Metabolic inhibition induces pyroptosis in uveal melanoma. (PubMed, Mol Cancer Res)
Although the bispecific tebentafusp is FDA-approved, immunotherapy has largely failed, likely given the poorly immunogenic nature of UM...In particular, the CPT1 inhibitor, etomoxir, induced propidium iodide uptake, caspase 3 cleavage and the release of HMGB1 and IL-1β, indicating that the observed cleavage of gasdermins led to pyroptosis...Together, these data show that metabolic inhibitors can induce pyroptosis in UM cell lines, potentially offering an approach to enhance inflammation-mediated immune targeting in metastatic UM patients. Implications: Induction of pyroptosis by metabolic inhibition may alter the tumor immune microenvironment and improve the efficacy of immunotherapy in uveal melanoma.
Journal • IO biomarker
|
CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • IL1B (Interleukin 1, beta) • CPT1A (Carnitine Palmitoyltransferase 1A) • GSDME (Gasdermin E) • CASP1 (Caspase 1)
|
Kimmtrak (tebentafusp-tebn) • etomoxir (MIQ-001)
6d
Non-RB1 germline cancer predisposing variants found in retinoblastoma patients. (PubMed, Genet Med Open)
In this small cohort of patients with retinoblastoma, non-RB1 variants did not appear to augment tumorigenesis or disease progression. Larger studies are required to determine associations between specific variants and development of SMN.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
6d
STEP-RB: Topotecan Episcleral Plaque for Treatment of Retinoblastoma (clinicaltrials.gov)
P1, N=26, Completed, The Hospital for Sick Children | Recruiting --> Completed | Trial completion date: Oct 2030 --> Oct 2024 | Trial primary completion date: Oct 2025 --> Oct 2024
Trial completion • Trial completion date • Trial primary completion date
|
topotecan • topotecan episcleral
7d
The significance of RB1 in multiple myeloma. (PubMed, Front Immunol)
In this respect, RB1 loss has been implicated in the progression of MM through its influence on interleukin-6 (IL-6) secretion and cell proliferation. This review comprehensively summarizes the role of RB1 in MM and expounds on the potential of targeting RB1 as a therapeutic strategy for this malignancy.
Review • Journal
|
TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • IL6 (Interleukin 6) • RAS (Rat Sarcoma Virus)
|
TP53 mutation • RB1 deletion
7d
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
P2, N=32, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
Trial completion date • Trial primary completion date • Metastases
|
Mektovi (binimetinib) • Beleodaq (belinostat)
7d
Age distribution of retinoblastoma tumours in familial disease. (PubMed, Eye (Lond))
This supports the notion that it may be safe to reduce the length of surveillance for new tumours in familial retinoblastoma from 7 years of age.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
7d
Actin-based deformations of the nucleus control mouse multiciliated ependymal cell differentiation. (PubMed, Dev Cell)
A player in this process is the retinoblastoma 1 (RB1) protein, whose phosphorylation prompts MCIDAS activation. Overall, this study identifies a role for actin-based mechanical inputs to the nucleus as controlling factors in cell differentiation.
Preclinical • Journal
|
RB1 (RB Transcriptional Corepressor 1)
9d
New trial
|
RB1 (RB Transcriptional Corepressor 1)
9d
Psychoeducation for Uveal Melanoma (clinicaltrials.gov)
P=N/A, N=108, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
9d
SLNP-based CDK4- targeted nanotherapy against glioblastoma. (PubMed, Front Oncol)
Sil and SLNP-Sil effectively inhibited U87 and U251 cell migration 24 h after treatment. Our results indicated that Sil and SLNP-Sil are promising therapeutic approaches against glioblastoma and merit in vivo experimental verification using orthotropic xenograft mouse models against glioblastoma.
Journal
|
CDK4 (Cyclin-dependent kinase 4)
10d
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (clinicaltrials.gov)
P2, N=51, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | Trial completion date: Sep 2028 --> Nov 2026 | Trial primary completion date: Jan 2027 --> May 2025
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
10d
Highly asymmetric early presentation of FEVR requiring enucleation. (PubMed, Ophthalmic Genet)
Affected children present at an early age and advanced stages of disease. This case highlights that FEVR can have a highly asymmetric and advanced presentation at an early age and must be distinguished from retinoblastoma in the differential diagnosis of leukocoria.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1)
10d
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. (PubMed, Eur J Cancer)
Both treatment sequences are clinically feasible. A clinical benefit was noted in the sequential combination of ICIs followed by tebentafusp. This observation is limited by the retrospective nature of the study and merits further investigation in prospective clinical trials.
Journal • Checkpoint inhibition • IO biomarker • Metastases
|
GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
|
GNAQ mutation
|
Kimmtrak (tebentafusp-tebn)
14d
Precision Control of Cell Type-Specific Behavior via RNA Sensing and Editing. (PubMed, Small Methods)
Notably, the system also shows an excellent in vivo safety profile. In conclusion, the CRISPR-ADAReader system represents a groundbreaking method for the detection and editing of RNA, offering a potent instrument for the customized and precise governance of cell behavior.
Journal
|
ADAR (Adenosine Deaminase RNA Specific)
14d
Iridociliary adenoma with ballooning change in a dog. (PubMed, J Vet Med Sci)
Immunohistochemically, the cells were positive for vimentin, neuron-specific enolase, and S100, and negative for cytokeratin AE1/AE3, Iba-1, CD204, MelanA, Sox10, and PNL2. Based on these findings, the lesion was diagnosed as an iridociliary adenoma with ballooning change.
Journal
|
SOX10 (SRY-Box 10) • VIM (Vimentin) • MSR1 (Macrophage Scavenger Receptor 1)
14d
CA224-094: Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
P2, N=27, Active, not recruiting, Jose Lutzky, MD | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Jan 2024
Trial completion date • Trial primary completion date • Metastases
|
LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Opdivo (nivolumab) • relatlimab (BMS-986016)
14d
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma (clinicaltrials.gov)
P2, N=6, Active, not recruiting, Providence Health & Services | Recruiting --> Active, not recruiting | N=30 --> 6 | Trial primary completion date: Jun 2025 --> Dec 2024
Enrollment closed • Enrollment change • Trial primary completion date • Checkpoint inhibition • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
15d
New P2 trial • Metastases
|
roginolisib (IOA-244)
15d
Re-envisioning genetic predisposition to childhood and adolescent cancers. (PubMed, Nat Rev Cancer)
In this Review, I describe our current knowledge of genetic predisposition to childhood and adolescent cancers. Survival rates in children and adolescents with cancer and CPGs are often poor, necessitating better integration of genomic testing into clinical care to improve cancer prevention, surveillance and therapies.
Review • Journal
|
RB1 (RB Transcriptional Corepressor 1)
16d
Enrollment closed
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
melphalan
17d
Systematic drug screening and target analysis identify digitoxin as a potential therapy for uveal melanoma. (PubMed, Br J Pharmacol)
Given UVM's limited options, our study highlights the potential of digitoxin as a promising novel therapeutic agent for this aggressive and rare ocular cancer. Our comprehensive approach is effective in identifying the potent, cancer-specific therapeutic agents from herbal plants.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
17d
ATOM: Adjuvant Tebentafusp in High Risk Ocular Melanoma (clinicaltrials.gov)
P3, N=290, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting --> Recruiting
Enrollment open
|
Kimmtrak (tebentafusp-tebn)
19d
Tissue factor signalling modifies the expression and regulation of G1/S checkpoint regulators: Implications during injury and prolonged inflammation. (PubMed, Mol Med Rep)
It is hypothesised that the balance of this signal is also dependent on the ability of cells to moderate the TF, and therefore on the level of damage. However, prolonged exposure of cells for example due to inflammation, leads to the dysregulation of the G1/S checkpoint by the tumour suppressors, leading to aberrant growth.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NES (Nestin)
|
NES expression • CDKN2A expression
20d
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
P1/2, N=253, Recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jun 2024 --> Jun 2025
Trial primary completion date • Metastases
|
HER-2 negative
|
FPI-1434
20d
Association of the expression of Bcl-2 and Ki-67 prognostic markers and apoptotic index with biological behaviour in aggressive and non-aggressive non-melanoma eyelid skin cancer. (PubMed, Postepy Dermatol Alergol)
A recurrence of the disease was observed in 4 (0.06%) cases. New information on cancer biomarkers in non-melanoma eyelid skin carcinoma contributes to choosing a correct therapy with achieving good aesthetic results and a good survival rate.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
21d
De Novo RB1 Germline Variant in Retinoblastoma with Two Subsequent Independent Neoplasms: Case Report and Literature Review. (PubMed, Int J Mol Sci)
In addition, we identified only three cases with two SMNs following RB diagnosis, with at least one of these being an EWS. This case broadens the clinical and genetic landscape of RB, demonstrates the importance of a multidisciplinary approach in these patients, and highlights genetic diagnosis as a mandatory feature for management.
Review • Journal
|
RB1 (RB Transcriptional Corepressor 1)
21d
BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells. (PubMed, Int J Mol Sci)
Doravirine was particularly effective in reactivating apoptosis and reducing cell growth in highly proliferative resistant cells by increasing tumor-suppressor proteins p16Ink4a and p27Kip1. These findings suggest that antiretroviral drugs can influence apoptosis and cell proliferation in RAF-inhibitor-resistant melanoma cells, offering potential therapeutic strategies for overcoming drug resistance.
Preclinical • Journal
|
BRAF (B-raf proto-oncogene) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
BRAF mutation
|
Tafinlar (dabrafenib) • AZ 628
21d
Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer. (PubMed, Biomolecules)
Moreover, bioactive Chaga components exerted a synergistic action with cisplatin and with trastuzumab in SK-BR-3 cells by inhibiting both HER2 and HER1 activation and displayed an immunomodulatory effect. Thus, Inonotus obliquus represents a source of triterpenoids that are effective against aggressive BC subtypes and display properties of targeted drugs.
Journal
|
EGFR (Epidermal growth factor receptor) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4)
|
HER-2 positive
|
Herceptin (trastuzumab) • cisplatin
22d
Phase 1/2 Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. (PubMed, Clin Cancer Res)
The combination of alisertib and pembrolizumab was well tolerated and led to prolonged SD in some immunotherapy-resistant patients, supporting our hypothesis that Aurora kinase A inhibition can reverse immunotherapy resistance of retinoblastoma protein-deficient HNSCC.
P1/2 data • Journal
|
AURKA (Aurora kinase A)
|
Keytruda (pembrolizumab) • alisertib (MLN8237)
24d
Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer. (PubMed, Exp Ther Med)
In conclusion, results from the present study suggest that ELF1 is overexpressed in GC. ELF1 combined with MMP9 can serve as a predictor of malignant biological behavior in GC and therefore a prognostic indicator for patients, due to its association with the tumor microenvironment.
Journal
|
KDR (Kinase insert domain receptor) • MLH1 (MutL homolog 1) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CDH1 (Cadherin 1) • CD4 (CD4 Molecule) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • MMP9 (Matrix metallopeptidase 9) • ELF1 (E74 Like ETS Transcription Factor 1) • PI3K (Phosphoinositide 3-kinases)
|
MMP9 overexpression
24d
Enrollment open • Combination therapy
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • melphalan
26d
RB Loss in p53 Abnormal Endometrial Carcinoma: Histological and Clinicopathological Correlates. (PubMed, Mod Pathol)
These findings highlight distinct morphomolecular features in RB-lost p53abn EC and confirm the utility of RB IHC as a surrogate for molecular RB1 alterations. This is the first study to show the potential use of RB in prognostic refinement of p53abn EC, although validation is warranted.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
26d
Orbital granular cell tumor involving the superior rectus muscle: a case report. (PubMed, Front Oncol)
For patients with incomplete tumor resection, close follow-up is necessary. Proton beam radiation therapy can be considered to prevent recurrence or metastasis if needed.
Journal
|
VIM (Vimentin) • CD68 (CD68 Molecule)
29d
Retinoblastoma programme outcome over a 10-year period in Lebanon: assessment of potential impact of the pandemic and economic crisis. (PubMed, Eye (Lond))
Our retinoblastoma programme demonstrated continued improved outcomes in terms of early detection, treatment, RB mutation detection, and eye preservation, despite the different challenges posed by the economic crisis and pandemic.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 mutation
29d
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer. (PubMed, Clin Cancer Res)
The combination of abemaciclib and fulvestrant has promising activity with durable responses in advanced or recurrent EC; a randomized trial is planned.
P2 data • Journal • MSi-H Biomarker • Metastases
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1)
|
HR positive • MSI-H/dMMR • PGR expression
|
Verzenio (abemaciclib) • fulvestrant
30d
Cone-rod homeobox transcriptionally activates TCF7 to promote the proliferation of retinal pigment epithelial and retinoblastoma cells in vitro. (PubMed, Int J Ophthalmol)
CRX transcriptionally activates TCF7 to promote the proliferation of RPE and RB cells in vitro. CRX is a potential target for RPE-based regenerative medicine. The potential risk of this strategy, tumorigenic potential, should be considered.
Preclinical • Journal
|
CCND1 (Cyclin D1) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3) • FOSL1 (FOS Like 1) • JUN (Jun proto-oncogene) • MMP7 (Matrix metallopeptidase 7) • TCF7 (Transcription Factor 7)
1m
Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma. (PubMed, J Immunother Cancer)
We also explore molecular and histological features of secondary resistance. Our case highlights that PD-1-resistant melanomas should be screened for GNAQ/11 mutations, as tebentafusp may be a treatment option in this extremely rare disease.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
GNAQ (G Protein Subunit Alpha Q) • PD-1 (Programmed cell death 1)
|
GNAQ mutation
|
Kimmtrak (tebentafusp-tebn)
1m
Gq/G11 oncogenic mutations promote PD-L1 expression and suppress tumor immunity. (PubMed, Eur J Cell Biol)
Furthermore, silencing YAP or treating with its inhibitor, Verteporfin, attenuated PD-L1 expression induced by Gq/G11 mutations, thereby enhancing T cell activation and T cell-mediated cytotoxicity. Collectively, this study reveals a potential role of Gq/G11 mutations on immune evasion of UM, a new mechanism of Gq/11 mutations-induced tumorigenesis, highlighting Gq/G11 and YAP as potential immunotherapeutic targets and suggesting Verteporfin as an adjuvant for immunotherapy of UM patients with GNAQ or GNA11 mutations.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
|
PD-L1 expression • GNAQ mutation • GNA11 mutation
|
Visudyne (verteporfin)
1m
Rapidly enlarging primary cutaneous anaplastic large T-cell lymphoma of the eyelid: A case report. (PubMed, J Pak Med Assoc)
Computed tomography (CT) scanning of the orbit revealed no extension, and positron emission tomography-computed tomography (PET-CT) showed no systemic involvement. The patient underwent surgical excision without adjuvant chemoradiation and has remained in clinical remission for five months.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive